Cabaletta Bio Valuation: Insider Buying and FDA Clearance for Automated CAR T Manufacturing

Cabaletta Bio (CABA) has seen a 34.7% 30-day share price return and a 33.5% year-to-date share price return, but its 3-year total shareholder return of 74.3% and 5-year total shareholder return of 76.9% highlight a weaker long-term record. With a share price of $2.95 and an analyst average price target of $13.13, the stock is considered undervalued with a price-to-book ratio of 2.2x, which is below the US Biotechs industry average and peer average. However, there are key risks including clinical setbacks and future capital raises that could further dilute existing shareholders.